Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective
Gary Benson,1 Tim Morton,2 Huw Thomas,3 Xin Ying Lee4 1Northern Ireland Haemophilia Comprehensive Care Centre and Thrombosis Unit, Belfast City Hospital, Belfast, UK; 2DRG, Bicester, UK; 3Biopharm, Novo Nordisk Ltd, Gatwick, UK; 4Biopharm Access, Novo Nordisk A/S, Søborg, DenmarkCorrespondence: Xin...
Saved in:
Main Authors: | Benson G (Author), Morton T (Author), Thomas H (Author), Lee XY (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
by: Mancuso ME, et al.
Published: (2014) -
Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
by: Hassan Abolghasemi, MD, et al.
Published: (2018) -
Changes in Quality of Life, Adherence, and Kinesiophobia in Patients with Hemophilia Treated with Extended Half-Life Treatment: Final Results of the LongHest Project
by: Roberto Ucero-Lozano, et al.
Published: (2024) -
Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
by: Di Ai, et al.
Published: (2022) -
Rescue of the endogenous FVIII expression in hemophilia A mice using CRISPR-Cas9 mRNA LNPs
by: Chun-Yu Chen, et al.
Published: (2024)